Aclaris Therapeutics Inc
ACRS
Get informed when a big investor buys or sells
+ FollowMarket Cap$768.15M
Close$
$-0.85
115.8% downside
Current Fair Value
115.8% downsideOvervalued by 115.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $768.15 Million |
|---|---|
| Enterprise Value | $752.96 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.53 |
| Beta | 0.8 |
| Outstanding Shares | 142,736,848 |
Return
| Return on Equity | -60.79% |
|---|---|
| Return on Assets | -42.15% |
| Return on Invested Capital | -53.25% |
Valuation & Multiples
| P/E Ratio | -9.48 |
|---|---|
| PEG | -24.08 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 91.61 |
| Enterprise Value to EBIT | -9.34 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
$1.33 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
$1.30 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2607▼ 10.75% |
|---|---|
| Total Calls | 602,700▼ 6.44% |
| Total Puts | 157,100▼ 33.77% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 83.71%▼ 0.69% |
|---|---|
| Total Invested | $631.87M▲ 55.04% |
| Investors Holding | 156▲ 16.00% |
ESG Score
No data
About Aclaris Therapeutics Inc
CEO: Neal Walker